Wellinks is excited to announce the final results of ASPIRE – a clinical trial conducted with the COPD Foundation to assess the impact of Wellinks on quality of life, engagement and satisfaction among COPDF members living with COPD.
Each participant received personalized health coaching, virtual pulmonary rehabilitation, and monitoring through connected devices and a patient-facing app.
The study enrolled 141 members in the trial, with 119 completing the 24-week study. These results demonstrate sustained engagement, satisfaction, and clinical response with Wellinks.
Wellinks Engagement at 24 Weeks
(n = 141)
61%
Enrollment Rate
Proportion successfully enrolled out of all who were interested and eligible
84%
Retention Rate
Proportion who remained enrolled in the study at 24 weeks
These results were demonstrated in a population with...
High Member Satisfaction at 24 Weeks
- Over 81% said Wellinks helped them better manage their COPD
- Over 92% found Wellinks to be valuable
- Over 83% said Wellinks helped them learn more about their COPD
* Net Promoter Score (NPS) is a customer loyalty and satisfaction measurement taken from asking customers how likely they are to recommend your product. NPS scores range from -100 to +100. This NPS is based on responses from those who continued contact with coaches, representative of the Wellinks clinical model.
Improved Clinical Outcomes at 24 Weeks
Wellinks demonstrated sustained improvements in COPD self-efficacy as measured by the COPD Self-efficacy Scale (CSES) at 24 weeks.
Self-efficacy is a measure of how confident an individual is in managing their COPD and addressing shortness of breath.
One-third of participants demonstrated improvements in Modified Medical Research Council dyspnea score. mMRC is a measure of breathlessness that is associated with risk of future exacerbations.
Sign up to stay updated on ASPIRE and Wellinks.
.png)
